The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
David F. McDermott
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Prometheus (Inst)
 
Marc Ryan Matrana
No Relationships to Disclose
 
Sun Young Rha
No Relationships to Disclose
 
Amado J. Zurita
Honoraria - Janssen Oncology; Pfizer
Consulting or Advisory Role - Exelixis
Research Funding - Infinity Pharmaceuticals; Pfizer
 
Thai Huu Ho
No Relationships to Disclose
 
Bhumsuk Keam
No Relationships to Disclose
 
Jae-Lyun Lee
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai
Research Funding - Bristol-Myers Squibb; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech
 
Richard Wayne Joseph
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Exelixis; Genoptix; Merck (Inst); Nektar; Novartis
Research Funding - Amgen (Inst); Bristol-Myers Squibb; Merck; Roche/Genentech (Inst); X4 Pharma (Inst)
 
Sarah Ali
No Relationships to Disclose
 
Walter Michael Stadler
Honoraria - AstraZeneca; Bristol-Myers Squibb; CVS Caremark; Sotio
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CVS Caremark; Sotio
Research Funding - Active Biotech (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech
Other Relationship - American Cancer Society; UpToDate
 
Naomi B. Haas
Consulting or Advisory Role - Cerulean Pharma; Exelixis; Janssen Oncology; Novartis; Pfizer
Expert Testimony - Lilly (I)
 
Srinath Sundararajan
No Relationships to Disclose
 
Se Hoon Park
Consulting or Advisory Role - Lilly
Speakers' Bureau - Lilly
 
Rex B. Mowat
No Relationships to Disclose
 
Joel Picus
Consulting or Advisory Role - Novo Nordisk
Research Funding - Agensys (Inst); Altor BioScience (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Innocrin Pharma (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Rexahn Pharmaceuticals (Inst); Seagen (Inst)
 
Arkadiusz Z. Dudek
Employment - Adhaere Pharmaceuticals
Leadership - IGF Oncology; Martell diagnostic
Stock and Other Ownership Interests - Biothera; IGF Oncology; Vanquish Oncology
Honoraria - Biothera; IGF Oncology; Medtronic; Vanquish Oncology
Consulting or Advisory Role - Biothera; TTC Oncology; Vanquish Oncology
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Castle Biosciences; Eisai; Exelixis; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Newlink Genetics
 
Lu Gan
Employment - X4 Pharma
Stock and Other Ownership Interests - X4 Pharma
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Alexion Pharmaceuticals; Argos Therapeutics; Array BioPharma; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Celldex; Eisai; Exelixis; Genentech; Glactone Pharma; Idera; Merck; Nektar; Novartis; Peleton; Pfizer; X4 Pharma